冬凌草甲素对MG-63细胞的增殖抑制、凋亡诱导和转移抑制作用及分子机制
|
摘要
研究背景:骨肉瘤是最常见的高度恶性的原发性骨肿瘤,好发于青少年,死亡率高。目前骨肉瘤的主要治疗手段为手术辅助化疗。虽然病人的生存率已得到了显著的提高,但对于伴有转移的骨肉瘤目前仍无有效的治疗手段;化疗耐药和化疗后继发肿瘤也是骨肉瘤治疗过程中面临的难题。因此,寻找新的治疗方法仍是当前研究的热点。冬凌草甲素是从冬凌草等植物中提取出来的一种天然活性物质,具有抗炎、抗DNA突变、抗氧化作用。目前研究证明,冬凌草甲素对多种肿瘤具有生长抑制作用,有望成为一种高效、低毒的新型抗肿瘤药物。本研究用冬凌草甲素作用于人骨肉瘤细胞株——MG-63细胞株,观察冬凌草甲素对MG-63细胞是否具有抑制增殖、凋亡诱导和转移抑制作用,并对其分子机制进行部分揭示。
第一章冬凌草甲素对MG-63细胞的增殖抑制效应
目的:确定冬凌草甲素是否具有抑制MG-63细胞增殖的能力。
方法:用不同浓度的冬凌草甲素干预MG-63细胞,通过台盼蓝拒染试验、MTT试验和细胞的药物浓度—时间生长曲线分析观察其对MG-63细胞活力的影响;通过流式细胞仪检测MG-63细胞的细胞周期变化。
结果:(1)冬凌草甲素能以时间和浓度依赖性方式有效的抑制MG-63细胞增殖,药物抑制MG-63细胞活力的IC50约为13μmol/L。
(2)冬凌草甲素能增加MG-63细胞G0/G1期百分率,降低MG-63细胞S期百分率,细胞增殖指数下降。
结论:冬凌草甲素能够有效的抑制MG-63细胞的增殖,并呈时间和药物浓度依赖性。
第二章冬凌草甲素对MG-63细胞的凋亡诱导效应
目的:确定冬凌草甲素是否能诱导MG-63细胞凋亡。
方法:用不同浓度的冬凌草甲素作用于MG-63细胞,用Hochest33258染色鉴定MG-63细胞凋亡的形态学特征;用流式细胞仪分析MG-63早期凋亡细胞的百分率;用Caspase-8蛋白印迹分析证明MG-63细胞凋亡发生的分子特征。
结果:(1)凋亡细胞形态学鉴定、流式细胞仪检测均有力证明冬凌草甲素能以浓度依赖性方式诱导MG-63细胞凋亡。(2)冬凌草甲素诱导MG-63细胞凋亡伴有Caspase-8蛋白表达上调和裂解激活。
结论:冬凌草甲素能以浓度依赖性方式诱导MG-63细胞凋亡。
第三章冬凌草甲素对MG-63细胞增殖抑制和凋亡诱导效应的分子机制
目的:(1)揭示冬凌草甲素抑制MG-63细胞增殖与细胞周期改变的关系;(2)部分揭示冬凌草甲素对MG-63细胞凋亡诱导的分子机制;(3)确定Caspase-8活化在冬凌草甲素诱导的MG-63细胞凋亡中的重要作用。
方法:(1)流式细胞仪检测细胞周期变化;(2)Western印迹检测CyclinD1、P21以及凋亡相关蛋白Survivin、Bcl-2和Bax蛋白表达的变化;(3)TRAP-PCR-ELISA方法检测MG-63细胞端粒酶活性的变化;(4)Z-IETD-fmk阻断试验检测Caspase-8阻断后,冬凌草甲素对MG-63细胞凋亡影响的变化。
结果:(1)冬凌草甲素增加G0/G1期MG-63细胞百分率,降低S期MG-63细胞百分率;(2)冬凌草甲素以浓度依赖性方式抑制MG-63细胞的CyclinD1、Survivin和Bcl-2蛋白表达,而P21和Bax蛋白表达上调;(3)冬凌草甲素以浓度依赖性方式抑制MG-63细胞端粒酶的活性;(4)Z-IETD-fmk阻断Caspase-8活性后,能部分逆转和减弱冬凌草甲素对MG-63细胞的凋亡诱导作用。
结论:冬凌草甲素通过影响细胞周期调节蛋白、阻断细胞周期G1/S期“稽查点”;抑制Survivin、Bcl-2,上调Bax;抑制端粒酶活性以及活化Caspase-8等途径抑制MG-63细胞增殖及诱导MG-63细胞凋亡。
第四章冬凌草甲素对MG-63细胞转移的抑制效应和分子机制
目的:确定冬凌草甲素是否具有抑制MG-63细胞转移的能力及其分子机制。
方法:用不同浓度的冬凌草甲素作用于MG-63细胞,用体外驱化运动试验检测MG-63细胞运动驱化能力的变化;用RT-PCR检测MG-63细胞中VEGF和MMP-9 mRNA表达的变化;用ELISA方法检测MG-63细胞上清VEGF和MMP-9浓度的变化。
结果:(1)体外驱化运动试验证明冬凌草甲素能以浓度依赖性方式抑制MG-63细胞转移。(2)冬凌草甲素以浓度依赖性方式抑制MG-63细胞及其上清中VEGF和MMP-9的表达。
结论:冬凌草甲素具有抑制MG-63细胞转移的能力,其机制可能与药物下调VEGF和MMP-9有关。
Background:Osteosarcoma is the most common high-grade primary bone tumor and usually occurs in adolescents and children.The treatment of choice for osteosarcoma is neoadjuvant chemotherapy. However,despite substantial improvements in patient survival,no effective therapy is available for metastatic osteosarcoma.The frequent acquisition of drug-resistant phenotypes and the occurrence of second malignancies often associated with chemotherapy remain serious problems.New therapeutic strategies must be evaluated to improve survival.Oridonin is a naturally active substance isolated from Rabdosia rubescens.The medicinal value of oridium has been well recognized due to its anti-inflammation and anti-DNA-damaging effects.In recent years, many studies have shown that oridonin possesses anti-proliferative and apoptotic activities against various cancer cells with little toxicity.In our study,we observe whether Oridonin suppresses proliferation,induces apoptosis and inhibits metastasis of MG-63 cells and to explore its possible mechanisms.
PartⅠProliferation-inhibiting effect of Oridonin on MG-63 cells
Objective:To determine proliferation-inhibiting capability of Oridonin on MG-63 cells.Methods:MG-63 cells were treated with different concentrations of Oridonin,then cell viability was analyzed with trypan blue exclusion test、MTT assay and drug concentration-time survival curve test;Cell cycle was tested by flow cytometry.
Results:(1)Oridonin effectively inhibited the proliferation of MG-63 cells in a concentration-time dependent way,and the IC50 of MG-63 cells was 13μmol/L.(2)Oridonin increased the percentage of G0/G1 phase and decreased S phase of MG-63 cells.
Conclusion:Oridonin can inhibit proliferation of MG-63 cells effectively with a concentration-time dependent manner.
PartⅡApoptosis-inducing effect of Oridonin on MG-63 cells
Objective:To ensure whether Oridonin can induce the apoptosis of MG-63 cells.
Methods:After MG-63 cells were incubated with different concentrations of Oridonin,(1)morphologic character of apoptosis was evaluated by Hochest33258 staining;(2)the percentage of earlier apoptosis cell was analyzed by flow cytometry;(3)the molecular character of apoptosis was analyzed by Western blot detecting Caspase-8 expression.
Results:(1)Hochest33258 staining and flow cytometry detection powerfully testify Oridonin can induce the apoptosis of MG-63 cells in a concentration-dependent way;(2)The apoptosis of MG-63 cells,which was induced by Oridonin,kept company with up-regulation and cleavage of Caspase-8.
Conclusion:Oridonin can induce the apoptosis of MG-63 cells with a concentration-dependent manner.
PartⅢMolecular mechanisms of the proliferation-inhibiting and apoptosis-inducing effects of Oridonin on MG-63 cells
Objective:(1)To reveal the relation between the proliferationinhibiting effect of Oridonin and the change of MG-63 cells cycle;(2)To partly explore the mechanism of apoptosis-inducing effects of Oridonin on MG-63 cells;(3)To determine the important role Caspase-8 plays in the apoptosis of MG-63 cells induced by Oridonin.
Methods:(1)The change of cell cycle was analyzed by flow cytometry;(2)The protein expression of CyclinD1,P21,Survivin,Bcl-2 and Bax in MG-63 cells were detected by Western blot;(3)The telomerase activities were detected with TRAP-PCR-ELISA;(4)After the activation of Caspase-8 was inhibited,the changes of proliferation-inhibiting and apoptosis-inducing effects of Oridonin were detected by Z-IETD-fmk blocking tests.
Results:(1)Oridonin increased the percentage of G0/G1 phase and decreased S phase of MG-63 cells;(2)Oridonin down-regulated CyclinD1,Survivin and Bcl-2,and up-regulated P21 and Bax protein in a concentration-dependent way in MG-63 cells;(3)Oridonin downregulated telomerase activities in a concentration-dependent way in MG-63 cells;(4)The apoptosis -inducing effects of Oridonin were partly suppressed after Z-IETD-fmk blocking the Caspase-8 activation of MG-63 cells.
Conclusion:Oridonin inhibits proliferation and induces apoptosis of MG-63 cells through regulating cell cycle protein,blocking "checkpoint" of G1/S phase,down-regulating CyclinD1,Survivin and Bcl-2, up-regulated P21 and Bax and activating Caspase-8.
PartⅣMetastasis-inhibiting effect of Oridonin on MG-63 cells and its mechanism
Objective:To determine metastasis-inhibiting capability of Oridonin on MG-63 cells and to explore its mechanisms.
Methods:After MG-63 cells were incubated with different concentrations of Oridonin,(1)the metastasis ability was analyzed with experiment of chemotaxic migration;(2)the mRNA expressions of VEGF and MMP-9 were analyzed by RT-PCR;(3)the expressions of VEGF and MMP-9 were analyzed by ELISA.
Results:(1)Oridonin effectively inhibited the metastasis of MG-63 cells in a concentration-time dependent way.(2)Oridonin effectively inhibited the expressions of VEGF and MMP-9 in a concentration-time dependent way.
Conclusion:Oridonin can inhibit metastasis of MG-63 cells effectively with a concentration dependent manner and the molecular mechanism may relate to Oridonin down-regulating VEGF and MMP-9 expression.
第一章冬凌草甲素对MG-63细胞的增殖抑制效应
目的:确定冬凌草甲素是否具有抑制MG-63细胞增殖的能力。
方法:用不同浓度的冬凌草甲素干预MG-63细胞,通过台盼蓝拒染试验、MTT试验和细胞的药物浓度—时间生长曲线分析观察其对MG-63细胞活力的影响;通过流式细胞仪检测MG-63细胞的细胞周期变化。
结果:(1)冬凌草甲素能以时间和浓度依赖性方式有效的抑制MG-63细胞增殖,药物抑制MG-63细胞活力的IC50约为13μmol/L。
(2)冬凌草甲素能增加MG-63细胞G0/G1期百分率,降低MG-63细胞S期百分率,细胞增殖指数下降。
结论:冬凌草甲素能够有效的抑制MG-63细胞的增殖,并呈时间和药物浓度依赖性。
第二章冬凌草甲素对MG-63细胞的凋亡诱导效应
目的:确定冬凌草甲素是否能诱导MG-63细胞凋亡。
方法:用不同浓度的冬凌草甲素作用于MG-63细胞,用Hochest33258染色鉴定MG-63细胞凋亡的形态学特征;用流式细胞仪分析MG-63早期凋亡细胞的百分率;用Caspase-8蛋白印迹分析证明MG-63细胞凋亡发生的分子特征。
结果:(1)凋亡细胞形态学鉴定、流式细胞仪检测均有力证明冬凌草甲素能以浓度依赖性方式诱导MG-63细胞凋亡。(2)冬凌草甲素诱导MG-63细胞凋亡伴有Caspase-8蛋白表达上调和裂解激活。
结论:冬凌草甲素能以浓度依赖性方式诱导MG-63细胞凋亡。
第三章冬凌草甲素对MG-63细胞增殖抑制和凋亡诱导效应的分子机制
目的:(1)揭示冬凌草甲素抑制MG-63细胞增殖与细胞周期改变的关系;(2)部分揭示冬凌草甲素对MG-63细胞凋亡诱导的分子机制;(3)确定Caspase-8活化在冬凌草甲素诱导的MG-63细胞凋亡中的重要作用。
方法:(1)流式细胞仪检测细胞周期变化;(2)Western印迹检测CyclinD1、P21以及凋亡相关蛋白Survivin、Bcl-2和Bax蛋白表达的变化;(3)TRAP-PCR-ELISA方法检测MG-63细胞端粒酶活性的变化;(4)Z-IETD-fmk阻断试验检测Caspase-8阻断后,冬凌草甲素对MG-63细胞凋亡影响的变化。
结果:(1)冬凌草甲素增加G0/G1期MG-63细胞百分率,降低S期MG-63细胞百分率;(2)冬凌草甲素以浓度依赖性方式抑制MG-63细胞的CyclinD1、Survivin和Bcl-2蛋白表达,而P21和Bax蛋白表达上调;(3)冬凌草甲素以浓度依赖性方式抑制MG-63细胞端粒酶的活性;(4)Z-IETD-fmk阻断Caspase-8活性后,能部分逆转和减弱冬凌草甲素对MG-63细胞的凋亡诱导作用。
结论:冬凌草甲素通过影响细胞周期调节蛋白、阻断细胞周期G1/S期“稽查点”;抑制Survivin、Bcl-2,上调Bax;抑制端粒酶活性以及活化Caspase-8等途径抑制MG-63细胞增殖及诱导MG-63细胞凋亡。
第四章冬凌草甲素对MG-63细胞转移的抑制效应和分子机制
目的:确定冬凌草甲素是否具有抑制MG-63细胞转移的能力及其分子机制。
方法:用不同浓度的冬凌草甲素作用于MG-63细胞,用体外驱化运动试验检测MG-63细胞运动驱化能力的变化;用RT-PCR检测MG-63细胞中VEGF和MMP-9 mRNA表达的变化;用ELISA方法检测MG-63细胞上清VEGF和MMP-9浓度的变化。
结果:(1)体外驱化运动试验证明冬凌草甲素能以浓度依赖性方式抑制MG-63细胞转移。(2)冬凌草甲素以浓度依赖性方式抑制MG-63细胞及其上清中VEGF和MMP-9的表达。
结论:冬凌草甲素具有抑制MG-63细胞转移的能力,其机制可能与药物下调VEGF和MMP-9有关。
Background:Osteosarcoma is the most common high-grade primary bone tumor and usually occurs in adolescents and children.The treatment of choice for osteosarcoma is neoadjuvant chemotherapy. However,despite substantial improvements in patient survival,no effective therapy is available for metastatic osteosarcoma.The frequent acquisition of drug-resistant phenotypes and the occurrence of second malignancies often associated with chemotherapy remain serious problems.New therapeutic strategies must be evaluated to improve survival.Oridonin is a naturally active substance isolated from Rabdosia rubescens.The medicinal value of oridium has been well recognized due to its anti-inflammation and anti-DNA-damaging effects.In recent years, many studies have shown that oridonin possesses anti-proliferative and apoptotic activities against various cancer cells with little toxicity.In our study,we observe whether Oridonin suppresses proliferation,induces apoptosis and inhibits metastasis of MG-63 cells and to explore its possible mechanisms.
PartⅠProliferation-inhibiting effect of Oridonin on MG-63 cells
Objective:To determine proliferation-inhibiting capability of Oridonin on MG-63 cells.Methods:MG-63 cells were treated with different concentrations of Oridonin,then cell viability was analyzed with trypan blue exclusion test、MTT assay and drug concentration-time survival curve test;Cell cycle was tested by flow cytometry.
Results:(1)Oridonin effectively inhibited the proliferation of MG-63 cells in a concentration-time dependent way,and the IC50 of MG-63 cells was 13μmol/L.(2)Oridonin increased the percentage of G0/G1 phase and decreased S phase of MG-63 cells.
Conclusion:Oridonin can inhibit proliferation of MG-63 cells effectively with a concentration-time dependent manner.
PartⅡApoptosis-inducing effect of Oridonin on MG-63 cells
Objective:To ensure whether Oridonin can induce the apoptosis of MG-63 cells.
Methods:After MG-63 cells were incubated with different concentrations of Oridonin,(1)morphologic character of apoptosis was evaluated by Hochest33258 staining;(2)the percentage of earlier apoptosis cell was analyzed by flow cytometry;(3)the molecular character of apoptosis was analyzed by Western blot detecting Caspase-8 expression.
Results:(1)Hochest33258 staining and flow cytometry detection powerfully testify Oridonin can induce the apoptosis of MG-63 cells in a concentration-dependent way;(2)The apoptosis of MG-63 cells,which was induced by Oridonin,kept company with up-regulation and cleavage of Caspase-8.
Conclusion:Oridonin can induce the apoptosis of MG-63 cells with a concentration-dependent manner.
PartⅢMolecular mechanisms of the proliferation-inhibiting and apoptosis-inducing effects of Oridonin on MG-63 cells
Objective:(1)To reveal the relation between the proliferationinhibiting effect of Oridonin and the change of MG-63 cells cycle;(2)To partly explore the mechanism of apoptosis-inducing effects of Oridonin on MG-63 cells;(3)To determine the important role Caspase-8 plays in the apoptosis of MG-63 cells induced by Oridonin.
Methods:(1)The change of cell cycle was analyzed by flow cytometry;(2)The protein expression of CyclinD1,P21,Survivin,Bcl-2 and Bax in MG-63 cells were detected by Western blot;(3)The telomerase activities were detected with TRAP-PCR-ELISA;(4)After the activation of Caspase-8 was inhibited,the changes of proliferation-inhibiting and apoptosis-inducing effects of Oridonin were detected by Z-IETD-fmk blocking tests.
Results:(1)Oridonin increased the percentage of G0/G1 phase and decreased S phase of MG-63 cells;(2)Oridonin down-regulated CyclinD1,Survivin and Bcl-2,and up-regulated P21 and Bax protein in a concentration-dependent way in MG-63 cells;(3)Oridonin downregulated telomerase activities in a concentration-dependent way in MG-63 cells;(4)The apoptosis -inducing effects of Oridonin were partly suppressed after Z-IETD-fmk blocking the Caspase-8 activation of MG-63 cells.
Conclusion:Oridonin inhibits proliferation and induces apoptosis of MG-63 cells through regulating cell cycle protein,blocking "checkpoint" of G1/S phase,down-regulating CyclinD1,Survivin and Bcl-2, up-regulated P21 and Bax and activating Caspase-8.
PartⅣMetastasis-inhibiting effect of Oridonin on MG-63 cells and its mechanism
Objective:To determine metastasis-inhibiting capability of Oridonin on MG-63 cells and to explore its mechanisms.
Methods:After MG-63 cells were incubated with different concentrations of Oridonin,(1)the metastasis ability was analyzed with experiment of chemotaxic migration;(2)the mRNA expressions of VEGF and MMP-9 were analyzed by RT-PCR;(3)the expressions of VEGF and MMP-9 were analyzed by ELISA.
Results:(1)Oridonin effectively inhibited the metastasis of MG-63 cells in a concentration-time dependent way.(2)Oridonin effectively inhibited the expressions of VEGF and MMP-9 in a concentration-time dependent way.
Conclusion:Oridonin can inhibit metastasis of MG-63 cells effectively with a concentration dependent manner and the molecular mechanism may relate to Oridonin down-regulating VEGF and MMP-9 expression.
引文
[1] Uchida A. Recent advances in management of musculoskeletal tumors. Cancer Chemother, 1999, 26(Supp 1): 185-190.
[2] Ham SJ, Schraffordt Koopsh, Vander Graaf WT, et al. Historical, current and future aspects of osteosarcoma treatment. Eur J Surg Oncol, 1998, 24(6):584-600
[3] Picci P, Ferrari S, Bacci G, et al. Treatment recommendation for osteosarcoma and adult soft tissue sarcoma. Drugs, 1994, 47: 82-92.
[4] Bramwell VH. The role of chemotherapy in the management of non-metastatic operable extremity osteosarcoma. Semin Oncol, 1997, 24(5): 561-571.
[5] Bacci G, Lari S. Current treatment of high grade osteosarcoma of the extremity. J Chemother, 2001,13: 235-243.
[6] Wafa H, Grimer RJ. Surgical options and outcomes in bone sarcoma. Expert Rev Anticancer Ther, 2006, 6: 239-248.
[7] Tsunemi T, Nagoya S, Kaya M, et al. Postoperative progression of pulmonary metastasis in osteosarcoma. Clin Orthop Relat Res, 2003, 407:159-166.
[8] Yance DR, Sarga SM. Targeting angiogenesis with integrative cancer therapies. Integr Cancer Ther, 2006, 5(1): 9-29.
[9] Gonzales GF, Valerio LG. Medicinal plants from Peru: a review of plants as potential agents against cancers. Anticancer Agents Med Chem, 2006, 6(5):429-444.
[10] de la Taille A, Hayek OR, Burchardt M, et al. Role of herbal compounds (PC-SPES) in hormone-refractory prostate cancer: Two case reports. J Altern Complement Med 2000, 6: 449-451.
[11] Li XT, Lin C, Li PY. Characteristics of the cytostatic effects of oridonin in vitro. Acta Pharmacol Sin, 1986, 7:361-363.
[12] Ikezoe T, Chen S, Heber D, et al. Baicalin is a major component of PC-SPES which inhibits the proliferation of human cancer cells via apoptosis and cell cycle arrest. Prostate, 2001, 49: 285-292.
[13] Hsieh TC, Wijeratne EK, Liang JY, et al. Differential control of growth, cell cycle progression, and expression of NF-kappaB in human breast cancer cells MCF-7, MCF-10A, and MDA-MB-231 by ponicidin and oridonin, diterpenoids from the chinese herb Rabdosia rubescens. Biochem Biophys Res Commun,2005, 337(1): 224-231.
[14] Zhang JF, Liu JJ, Liu PQ, et al. Oridonin inhibits cell growth by induction of apoptosis on human hepatocellular carcinoma BEL-7402 cells. Hepatol Res,2006, 35:104-110.
[15] Leung CH, Grill SP, Lam W, et al. Novel mechanism of inhibition of nuclear factor-kappa B DNA-binding activity by diterpenoids isolated from Isodon rubescens. Mol Pharmacol, 2005, 68: 286-297.
[16] Ikezoe T, Yang Y, Bandobashi K, et al. Oridonin, a diterpenoid purified from Rabdosia rubescens, inhibits the proliferation of cells from lymphoid malignancies in association with blockade of the NF-kappa B signal pathways.Mol Cancer Ther, 2005, 4(4): 578-586.
[17] Ikezoe T, Chen SS, Tong XJ, et al. Oridonin induces growth the inhibition and apoptosis of a variety of human cancer cells. Int J Oncol, 2003, 23(4):1187-1193.
[18] Gabellini C, Antonelli A, Petrinelli P, et al. Telomerase activity, apoptosis and cell cycle progression in ataxia telangiectasia lymphocytes expressing TCL 1. Br J Cancer, 2003, 89(6): 1091-1095.
[19] Liu YQ, You S, Tashiro S, et al. Activation of phosphoinositide 3-kinase, protein kinase C, and extracellular signal-regulated kinase is required for oridonin-enha-nced phagocytosis of apoptotic bodies in human macrophage-like U937 cells. J Pharmacol Sci, 2005, 98: 361-371.
[20] Khar A, Ali AM, Pardhasaradhi BV. Induction of stress response renders human tumor cell lines resistant to curcumin-mediated apoptosis: role of reactive oxygen intermediates. Cell Stress Chaperones, 2001, 6(4): 368-376.
[21] Gao ZG, Ye QX, Zhang TM. Synergistic effect of oridonin and cisplatin on cytotoxicity and DNA cross-link against mouse sarcoma S180 cells in culture. Zhong Guo Yao Li Xue Bao,1993,14(6):561-564.
[22]Huang J,Wu L,Tashiro S,et al.Bcl-2 up-regulation and P-p53 down-regulation account for the low sensitivity of murine L929 fibrosarcoma cells to oridonin-induced apoptosis.Biol Pharm Bull,2005,28(11):2068-2074.
[23]司徒镇强,吴军正.细胞培养.西安:世界图书出版公司,2004,1-378.
[24]白丽,邬利娅,伊明,等.赤土茯苓对正常小鼠免疫功能的影响.新疆医科大学学报,2003,26(6):573-574.
[25]冯长伟,潘祥林,邹俊晖,等.冬凌草甲素对人红白血病细胞系K562生长的抑制作用.山东中医药大学学报,2000,24(3):225-226.
[26]Zhang CL,Wu LJ,Tashiro S,et al.Oridonin induced A375-S2 cell apoptosis via bax-regulated caspase pathway activation,dependent on the cytochrome c/caspase-9 apoptosome.J Asian Nat Prod Res,2004,6(2):127-138.
[27]Huang J,Wu L,Tashiro S,et al.Fibroblast growth factor-2 suppresses oridonin-induced L929 apoptosis through extracellular signal-regulated kinase-dependent and phosphatidylinositol 3-kinase-independent pathway.J Pharmacol Sci,2006,102(3):305-313.
[28]Li D,Wu LJ,Tashiro S,et al.Oridonin-induced A431 cell apoptosis partially through blockage of the Ras/Raf/Erk signal pathway.J Pharmacol Sci,2007,103(1):56-66.
[29]Liu YQ,You S,Tashiro S,et al.Oridonin induced U937 cell apoptosis through ERK pathway.Zhongguo Zhong Yao Za Zhi,2005,30(23):1856-1859.
[30]Kerr JFR,Wyllie AH,Currie AR.Apoptosis:a basic biological phenomenon with wide-ranging implications in tissue kinetics.Br J Cancer,1972,26:239-257.
[31]Kiechle FL,Zhang X.Apoptosis:biochemical aspects and clinical implications.Clin Chim Act,2002,326(1-2):27-45.
[32]Raynal P,Pollard HB.Annexins:the problem of assessing the biological role for a gene family of multifunctional calcium-and phospholipid-binding proteins.Biochim Biophys Acta.1994,1197(1):63-93.
[33]Vermes I,Haanen C,Steffens-Nakken H,et al.A novel assay for apoptosis:flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods, 1995,184(1): 39-51.
[34] Martin SJ, Reutelingsperger CP, McGahon AJ, et al. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J Exp Med, 1995,182(5): 1545-156.
[35] Koopman G, Reutelingsperger CP, Kuijten GA. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood, 1994, 84(5): 1415-1420.
[36] Homburg CH, de Haas M, von dem Borne AE, et al. Human neutrophils lose their surface Fc gamma RIII and acquire Annexin V binding sites during apoptosis in vitro. Blood, 1995, 85(2): 532-540.
[37] Mullauer L, Gruber P, Sebinger D, et al. Mutations in apoptosis genes: a pathogenetic factor for human disease. Mutat Res, 2001,488: 211-231.
[38] Kiechle FL, Zhang X. Apoptosis: a brief review. J Clin Ligand Assay, 1998, 21:58-61.
[39] Zimmerman KC, Bonzon C, Green DR. The machinery of programmed cell death. Pharmacol Ther, 2002, 92: 57-70.
[40] Reed JC. Mechanisms of apoptosis. Am J Pathol, 2000,157:1415-1430.
[41] Elledge SJ. Cell cycle checkpoints: preventing an identify crisis. Science, 1996, 274:1664-1671.
[42] 来茂德.医学分子生物学.北京:人民卫生出版社, 1999, 40-54.
[43] Saldanha SN, Andrews LG, Tollefsbol TO. Assessment of telomere length and factors that contribute to its stability. Eur J Biochem, 2003, 270(3): 389-403.
[44] Bianchi A, Smith S, Chong L, et al. TRF1 is a dimer and bends telomere DNA. EMBOJ, 1997,16(7): 1785-1794.
[45] Ren KK, Wang HZ, Xie LP, et al. The effects of Oridonin on cell growth, cell cycle, cell migration and differentiation in melanoma cells. J Ethnopharmacol,2006,16(2): 176-180.
[46] Kroemer G. The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat Med, 1997, 3: 614-619.
[47]Green DR,Reed JC.Mitochondria and apoptosis.Science,1998,281:1309-1311.
[48]Grooss A,McDonnell JM,Korsmeyer SJ.Bcl-2 family members and the mitochondria in apoptosis.Genes Deu,1999,13:1899-1911.
[49]Joza N.Essential role of the mitochondria apoptosis-inducing factor in programmed cell death.Nature,2001,410(6828):549-554.
[50]Shi h.A structural view of mitochondria-mediated apoptosis.Nat Biol,2001,8(5):394-401.
[51]申家英,杨波.冬凌草甲素对HL-60细胞的生长抑制作用及其对细胞端粒酶活性的调节.白血病·淋巴瘤,2003,12(4):224-226.
[52]Adida C,Crotty PL,Mcgrath J,et al.Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse proliferation.Am J Pathol,1998,152(1):43.
[53]Konno R,Yamakawa H,Utsunomiya H,et al.Expression of survivin and bcl-2 in the normal human endometrium.Mol Hum Reprod,2000,6(6):529.
[54]Shin S,Sung BJ,ChoYS,et al.An anti-apoptotic protein human survivor is a direct inhibitor of caspase-3 and caspase-7.Biochemistry,2001,40(4):1117-1123.
[55]Li F,Ambrosini G,Chu EY,et al.Control of apoptosis and mitotic spindle checkpoint by survivin.Nature(Lond),1998,396(6711):580-584.
[56]Suzuki A,Ito T,Kowano H,et al.Survivin initiates procaspase-3/p21 complex formation as a result of interaction with Cdk4 to resisit Fas-mediated death.Oncogene,2000,19:1346-1353.
[57]Sato N,Mizumoto K,Nagai E,et al.Telomerase as a new target for pancreatic cancer treatment.J Hepatobiliary Pancreat Surg,2002,9(3):322-327.
[58]Mese H,Ueyama Y,Suzuki A,et al.Inhibition of telomerase activity as a measure of tumor cell killing by cisplatin in squamous cell carcinoma cell line.Chemotherapy,2001,47(2):136-142.
[59]Jiang YA,Luo HS,Zhang YY,et al.Telomerase activity and cell apoptosis in colon cancer cell by human telomerase reverse transcriptase gene antisense oligodeoxynucleotide.World J Gastroenterol,2003,9(9):1981-1984.
[60]Gabellini C,Antonelli A,Petrinelli P,et al.Telomerase activity,apoptosis and cell cycle progression in ataxia telangiectasia lymphocytes expressing TCL1.Br J Cancer,2003,89(6):1091-1095.
[61]Zhu XL,Kumar R,Mandal M,et al.Cell cycle-dependent modulation of telomerase activity in tumor cells.Proc Natl Acad Sci USA,1996,93(7):6091-6095.
[62]Scott LA,Vass JK,Parkinson EK,et al.Invasion of normal human fibroblasts induced by v-Fos is independent of proliferation,immortalization,and the tumor suppressors p16INK4a and p53.Mol Cell Biol,2004,24(4):1540-1559.
[63]Kiyono T,Foster S,Koop JI,et al.Both Rb/P16~(INK4a)inactivity are required to immortalize human epithelial cells.Nature,1998,396(6706):84-88.
[64]Zhang LP,Jiang JK,Tam JW,et al.Effects of Matrine on proliferation and differentiation in K-562 cells.Leuk Res,2001,25(9):793-800.
[65]周峻,金岩,何勇,等.端粒酶抑制剂对舌癌细胞株端粒酶活性和细胞周期的作用.中国癌症杂志,2002,12(2):110-112.
[66]Noble JR,Zhong ZH,Neumann AA,et al.Alterations in the p16(INK4a)and p53 tumor suppressor genes of bTERT-immortalized buman fibroblasts.Oncogene,2004,23(17):3116-3121.
[67]李登举,张瑶珍,曹文静,等.细胞外调节蛋白激酶与端粒酶对肝癌和白血病细胞凋亡的调控作用研究.中国实验血液学杂志,2002,10(4):294-298.
[68]Nakatani K,Toshimi N,Mori H,et al.The significant role of telomerase activity in human brain tumors.Cancer,1997,80:471-472.
[69]Cong YS,Wright WE,Shay JW.Human telomerase and its regulation.Microbiol Mol Biol Rev,2002,66(3):407-425.
[70]Horikawa I,Cable PL,Afshari C,et al.Cloning and characterization of the promoter region of human telomerase reverse transcriptase gene.Cancer Res,1999,59(4):826-830.
[71]李瑞芳,王庆端.冬凌草甲素对K562细胞端粒酶活性调控及细胞周期的影响.药学学报,2004,39(11):865-868.
[72]Staddon AP,Lackman R,Robinson K,et al.Osteogenic sarcoma presenting with lung metastasis.Oncologist,2002,7(2):144-153.
[73]Thompson RC Jr,Cheng EY,Clohisy DR,et al.Results of treatment for metastatic osteosarcoma with neoadjuvant chemotherapy and surgery.Clin Orthop,2002,397:240-247.
[74]Kantor JO,Mccormick B,Steeg PS,et al.Inhibition of cell motility after nm23transfection of human and marine tumor cells.Cancer Res,1993,53(4):1971-1973.
[75]Miyasaka M.Cancer metastasis and adhesion molecules.Clin Orthop,1995,312:10-18.
[76]Opedenakker Q,Van Damme J.Chemotactic factors,passive invasion and metastasis of cancer cells.Immumol Today,1992,13(2):463-464.
[77]Balkwill F.Chemokine biology in cancer.Semin Immuno,2003,15(1):49-55.
[78]Itoh Y,Nagase H.Matrix metalloproteinases in cancer.Essays Biochem,2002,38:21-36.
[79]Cavallaro U,Christofori G.Cell adhesion in tumor invasion and metastasis:loss of the glue is not enough.Biochim Biophys Acta,2001,1552(1):39-45.
[80]Webb CP,Vande Woude GF.Genes that regulate metastasis and angiogenesis.J Neuro oncology,2000,50:71-87.
[81]韩锐,孙燕.新世纪癌的化学预防与药物治疗.第一版,北京:人民军医出版社,2005,307-319.
[82]Anitha J,George T.The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis.Patho Oncol Res,2004,7(1):14-23.
[83]Stanley Z,Cao J,Chen WT.Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment.Oncogene,2000,19(56):6642-6650.
[84]Kakeji Y,MaeharaY,Sumiyoshi Y,et al.Angiogenesis as a target for gastric cancer.Surgery,2002,131(1 Suppl):S48-54.
[85]Tosetti F,Ferrari N,De Flora S,et al.Angioprevention:angiogenesis is a common and key target for cancer chemopreventive agents.FASEB J,2002,16(1):2-14.
[86]Gerwins P,Skoldenberg E,Claesson Welsh L.Function of fibroblast growth factors and vascular endothelial growth factors and their receptors in angiogenesis. Crit Rev Oncol Hematol, 2000, 34(3): 185-194.
[87] Bruns CJ, Liu W, Davis DW, et al. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases. Cancer, 2000, 89(3): 488-499.
[88] Noda M, Hattori T, Kimura T, et al. Expression of fibroblast growth factor 2 mRNA in early and advanced gastric cancer. Acta Oncol, 1997, 36(7): 695-701.
[89] Meade-Tollin LC, Wijeratne EM, Cooper D, et al. Ponicidin and oridonin are responsible for the antiangiogenic activity of Rabdosia rubescens, a constituent of the herbal supplement PCSPES. J Nat Prod, 2004, 67(1): 2-4.
[90] Ren KK, Wang HZ, Xie LP, et al. The effects of oridonin on cell growth, cell cycle, cell migration and differentiation in melanoma cells. J Ethnopharmacol, 2006,103(2): 176-180.
[1] Rosen G, Tan C , Sanmaneechai A ,et al.The rationale for Multiple drug chemotherapy in the treatment of osteogenic sarcoma.[J]. Cancer, 1975,35(3S):936-945.
[2] Bramwell VH. The role of chemotherapy in the management of non- metastatic operable extremity osteosarcoma. [J] .Semin Oncol, 1997 , 24 (5): 561-571.
[3] Bacci G, Forni C, Ferrair S,et al.Neoadjuvant chemotherapy for osteo-sarcoma of extremity: Intensification of preoperative treatment does not increase the rate of good histologic response to the primary tumor or improve the final outcome.[J] .Pediatr Hematol Oncol, 2003, 25: 845-853.
[4] Goorin AM, SchwartzentruberDJ,DevidasM, et al. Presurgical chemtherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric oncolong groupstudy POG-8651. [J]. Clin Oncol, 2003,21:1574-1580.
[5] Eselgrim M, Grunert H, Kuhne T,et al. Dose intensity of chemotherapy for osteosarcoma and outcome in the cooperative osteosarcoma study group(COSS) trials. [J].Pediatr Blood Cancer. 2006, 47: 42-50.
[6] Wilkins RM , Cullen JW, Odom L, et al.Superior survival intreatment of primary nonmetastatic pediatric osteosarcoma of the extremity .[J].Ann Surg Oncol,2003 ,10 (5): 498-507.
[7] Abe S , Tateishi A , Ogawa K,et al . Long-term local intensive preoperative chemotherapy and joint-preserving conservative surgery for osteosarcoma around the knee. [J] .Ort hopedics , 2001,24 (7): 671-676.
[8] Fuchs N , Bielack SS , Epler D ,et al. Long-term results of the cooperative German-Aust rian-Swiss osteosarcoma study group, sprotocol COSS-86 of intensive multidrug chemotherapy and surgery for os teosarcoma of the limbs.[J].Ann Oncol, 1998 , 9 (8) :893-899.
[9]Scotland K, Baldni N, Serra M, et al. Adriamycin binding Assay:Avaluable chemosensitivity test in human osteosarcoma. [J]. Cancer Res Clin Oncol, 1992,119: 121-126.
[10] Baldini N, Scotlandi K, Serra M, et al.P-glycoprotein expression in osteosarcoma: A basis for risk-adapted adjuvant chemotherapy. [J] .OrthopRes, 1999, 17:629-632.
[11]SerraM,Scotlandi K,Reverter Branchat G,et al.Value of P-glycoprotein and linicopathologic factors as the basis for new treatment strategies in high-grand osteosarcoma of the extremities.[J].Clin Oncol,2003,21:536-542.
[12]Gasparini G.Metronomic scheduling:The future of chemotherapy.[J].Lan-cet Oncol,2001,2:640-733.
[13]Asada N,Tsuchiya H,Tomita K.Denovo deletions of p53 gene and wild-type p53 correlate with acquired cisplatin-resistance in human osteosarcoma OST cell line.[J].Anticancer Res,1999,19:5131-5137.
[14]于秀淳,刘晓平,周银,等.P糖蛋白在骨肉瘤组织中的表达与PCNA、p53、nm23蛋白表达的相关性.[J].中国矫形外科杂志,2000,7(3):224-226.
[15]严庆水,张惠平,苏增贵,等.珊瑚羟基磷灰石人工骨的研制和修复骨干缺损的实验研究.[J].中华骨科杂志,1996,11(4):726-728.
[16]范顺武,严世贵,杨迪生,等.保肢术结合辅助化疗治疗肢体B期骨肉瘤.[J].中华骨科杂志,2000,7(3):393-396.
[17]Luksch R,Perotti D,Cefalo G,et al.Immunomodulation in treatment program including pre-and post-operative interleukin-2 and chemotherapy for childhood osteosarcoma.[J].Tumor,2003,89(3):263-268.
[18]Liebau C,Roesel C,Schmidt S,et al.Immuno therapy by gene transfer with plasmids encoding IL-12/IL-18 is superior to IL-23/IL-18 gene transfer in a rat osteosarcoma mode.[J].Anticancer Res,2004,24(5A):2861-2867.
[19]Todesco A,Carli M,Iacona I,et al.All-trans retinoic acid and interferon-alpha in the treatment of a patient with resistant metastatic osteosarcoma,[J].Cancer,2000,89(12):2661-2666.
[20]Yee C.Thompson JA.Byrd D,et al.Adoptive T cell therapy using antigen specific CD8+ T cells.[J].Proc Natl Acad Sci USA,2002,99(25);16168-16173.
[21]Overwijk WW,Theoret MR,Findel stein SE,et al.Tumor Regression and Autoimmunity after Reversal of a Functionally Tolerant State of Self-reactive CD8+ T Cells.[J].ExpMed;2003;198(4);569-580.
[22]孙瑛勋,程绍辉,于鸣.等.CD3AK细胞过继免疫治疗的实验研究[J]细胞与分子免疫学杂志.2005;21(2);218-221
[23]Jiang J,Xu N,Wu C,et al.Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells.Anticancer Res,2006,26(3B):2237-2242.
[24]WongkajornsilpA.Sangsuriyong S.Hongeng S et al.Effective osteosarcoma cytolysis using cytokine-induced killer cells pre-inoculated with tumor RNA-pulsed dendritic cells.[J].OrthopRes,2005,23:1460-1466.
[25]Huang J,Kerstann KW,Ahmadzadeh M,et al,Modulation by IL-2 of CD70 and CD27 Expression on CD8~+ T Cells:Importance for the Therapeutic Effectiveness of Cell Transfer Immunotherapy.[J].Immunol,2006;176(12);7726-7735
[26]Nagaraj S Ziske C Schmidt-wolf IG,Human cytokine-induced killer cells have enhanced in vitro cytolytic activity via non-viral interleukin-2 gene transfer.[J].Genet Vaccines Ther,2004;2(1);12-14
[27]Ho WP.Yee C.Greeenberg PD.Adoptive therapy with CD8~+ T cells:it may get by with a little help from its friends.[J].Clin invest,2002;110(10);1415-1417.
[28]Ragland BD,BellWC,Lopez RR,et al.Cytogenetics and molecular biology of osteosarcoma.[J].Lab Invest,2002,82(4):365-373
[29]王桂龙,向阳,胡军.等.反义c-myc寡核苷酸对骨肉瘤MG-63细胞增殖和凋亡的影响.[J].中国骨肿瘤骨病,2007;2(6);14-17
[30]Cain K,Bratton SB,Langlais C,et al.Apaf-1 oligomerizes into biologically active approximately 700 kD and inactive ap2 proximately 114 MD apoptosome complexes.[J]Biol Chem,2000,275:6067-6070.
[31]蔡文涛,陈安民,郭风劲,等.HIF-1a反义寡核苷酸对骨肉瘤MG-63细胞HIF-1a、P53、Bcl-2表达及凋亡的影响.[J].中国癌症杂志,2006;11(16);948-852.
[32]Ravi R,Mookerjee B,Bhujwalla ZM,et al.Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1 alpha.[J].GenesDev,2000,14(1):34-44.
[33]段国庆,李书忠.凋亡抑制蛋白Survivin在骨肉瘤中的表达及其与PTEN cyclinD1蛋白表达的关系,[J].中国矫形外科杂志;2007;3(15);217-225.
[34]聂涛,戴闽,宗世璋.Survivin在骨肉瘤中的表达及其与血管内皮生长因子的相关性研究.[J].中国矫形外科杂志,2005,13(9):683-685.
[35]Trieb K,Lehner R,Stulnig T,et al.Survivin expression in human osteocarcoma is a marker for survival[J].Eur J Surg Oncol,2003,29(4):379-382.
[36]Conway EM,Pollefeyt S,Comelissen J,et al.Three differentially expressed Survivin cDNA variants encode proteins with distinct antiapoptosis function,[J].Blood,2000,95:1435-1442.
[37]Hollstein M,Sidransky D,Vogelstein B,et al.P53 mutation in human cancers.[J].Science,1991,253;49-53.
[38]李永昊,肖玉周,俞岚,等.P53、p16基因在骨肉瘤中表达及临床相关性研究.[J].中国骨肿瘤骨病,2007;3(6);162-167.
[39]AI-Mohanna MA,Manogaran PS,AI-Mukhalafi Z,et al.The tumor suppressor p16 INK4a)gene is a regulator of apoptosis induced by ultraviolet light and cisplatin[J].Oncogene,2004,23(1);201-212.
[40]Tsang WP,Chau SP,Fung KP,etal.Modulation of multidrug resistanceassociated protein 1(MRP1)by p53 mutant in Saos-2 cells.[J].Cancer Chemother Pharmacol,2003,51(2):161-166.
[41]Tsunemi T,Nagoya S,Kaya M,et al.Postopreative progression of pulmonary metastasis in osteosarcoma.[J].Clin OrthopRelat Res,2003,407:159-166.
[42]Semenza GL.Targeting HIF-1 for cancer therapy,[J].Nat Rev Cancer,2003,3:721-732.
[43]Mabjeesh NJ,Escuin D,LaVallee TM,et al.2ME2 inhibits tumor growth and angiogenesis by disrupting Microtubules and dysregulating HIF.[J].Cancer Cell,2003,3:363-375.
[44]吴强,杨述华,叶树楠,等.RNA干扰沉默缺氧诱导因子-1a治疗骨肉瘤的实验研究.[J].中华医学杂志,2005,85:409-413
[45]Takayama K,Ueno H,Nakanishi Y.Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ.[J].Cancer Res,2000,77:2169-2177.
[46]Charity RM,Foukas AF,Deshmukh NS,et al.Vascular endothelial growth factor expression in osteosarcoma.[J].Clin OrthopRelat Res,2006,448:193-198.
[47]Oda Y,Yamamoto H,Tamiya S,et al.CXCR4 and VEGF expression in the primary site and the metastatic site of human osteosarcoma:analysis with in a group of patients,all of whom developed lung metastasis.[J].Mod Pathol,2006,19:738-745.
[48]王燕,汪睿,乔慧,等.缺氧反应组件启动子表达反义血管内皮生长因子(VEGF)165cDNA靶向性抑制骨肉瘤细胞EGF表达.[J].中华病理杂志,2005,4:588-591.
[49]Falareau P,Champagne P,Poyet P,et al.Neovastat:a naturally occurring multifunctional antiangiogenic drug,in phase 3 clinical trials.[J].Semin Oncol, 2001,28:6-10.
[50]Kaya M,Wada T,Kawaguchi S,et al.Increased pre-therapeutic serum vascular endothelial growth factor in patients with early clinical relapse of osteosarcoma.[J].Br J Cancer,2002,86:864-869.
[51]OReilly MS,Boehm T,Shing Y,et al.Endostatin:an endogenous ingibitor of angiogenesis and tumour growth.[J].Cell,1997,88:277-285.
[52]Marshall E.Cancer therapy,set backs for endostatin.[J].Science,2002,295:2198-2199.
[53]Nyormoi O,Mills L,Rose RW,et al.An MMP-2/MMP-9 inhibitor,5a,enhances apoptosis induced by ligands of the YNF receptor superfamily in cancer cells.[J].Cell Death Differ,2003,10:558-569.
[54]吴朝阳,林建华.抑制血管生成治疗骨肉瘤的研究进展,[J].中国骨肿瘤骨病,2007,6;370-374.
[55]Masferrer JL,Leahy KM,Koki AT,et al.Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors.[J].Cancer Res,2000,60:1306-1311.
[56]肖涛,李康华,方建珍,等.三氧化二砷诱导骨肉瘤MG-3细胞凋亡的实验研究.[J].湖南省医科大学学报,2002,2;23-25.
[57]魏玲,王兴武,宋现让,等.三氧化二砷对人骨肉瘤细胞的体外效应.[J]中国药学杂志,2005,18;27-34
[58]王利民.苦参碱诱导骨肉瘤细胞凋亡的实验研究.[J].实用诊断与治疗杂志,2004,5;44-47
[59]陈永强,朱振安,戴克戎,等.蜂毒素对骨肉瘤细胞系细胞增殖的影响.[J]上海中医大学学院.2003,1;21-23.
[60]陈晓超,柯李晶,陈躬瑞,等。鹿茸粗提液对大鼠成骨肉瘤细胞增殖的调节作用.[J]中国中药杂志,2004,1;38-41.
[61]王进,沈靖南.粉防已碱逆转骨肉瘤细胞系多药耐药性的研究.[J].实用临床医学.2005,6;21-22
[62]王冠梁,王元,王琦中草药及其提取物治疗骨肉瘤的基础研究进展.[J].云南中医学院学报.2006,29(2);52-54.
[1]河南省医学科学研究所药理药化组,河南医学院化学教研组,云南省植物研究所植化室,等,一种新的抗肿瘤物质-冬凌草素[J].科学通报,1978,23(1):53-56
[2]Fujita T,Masudal I,Tka S,Fujita E.Antitumor aetivity of the Isodon diterpenoids:struetural requlrelnents for the activity,[J].ExPerientia,1976,32(2):203-206.
[3]刘晨江,赵志鸿.冬凌草的研究进展,[J].中国药学杂志,1998,33(10):577-581.
[4]刘净,梁敬钮,谢韬.冬凌草研究进展,[J].海峡药学,2004,16(2):1-7.
[5]冯长伟,潘祥林,邹俊晖,等.冬凌草甲素诱导HL60细胞凋亡的研究,[J]..山东医药,2000,40(6):7-8.
[6]王筠,刘清芸,华海婴,等.冬凌草甲素诱导HL60细胞凋亡[J]..中国药理学报,2001,17(4):402-405.
[7]栾凤君,杨纯正,马建国,等.一株人红白血病多药细胞系(K562/A02)的建立及其耐药特性的研究,[J]..中华肿瘤杂志,1993,15(2):101.
[8]郭娟娟,潘祥林,冯长伟,冬凌草甲素逆转多药耐药细胞系K562/A02耐药性的研究.上海医学,2002,25(1)34-35
[9]Li D,Wu LJ,Shiniehi T,etal.Oridonin-Indueed A431 Cell Apoptosis partially Through Blockage of the Ras、NFa、RK SignalPathway,[J].Phannaeol sci,2007,103(1):56-66.
[10]Huang J,Wu L,ShiniehiT,et al.A comparison of the 51,alpathwa between the TNF-a、INF-a and Oridonin-induced murine L929fibrosareoma cell death,[J].Aeta Med Okayama,2005,59(6):261-270.
[11]葛明,马用法,张中兴,等.冬凌草甲素和乙素对人肝癌BEL7402细胞株杀伤作用的研究,[J]药学通报,1981,16(5):6-7.
[12]刘加军,伍新尧,潘祥林,等.冬凌草甲素对ECA细胞的诱导凋亡机制,[J]中成药,2003,25(11):900-902
[13]王绵英,张覃沐.冬凌草甲素对几种肿瘤细胞M期作用机制的探讨,[J]癌症, 1984,8(2):84-85.
[14]寿马钢,张覃沐,薛绍白,等.用流式细胞光度术测定冬凌草甲素和博莱霉素A5合用对艾氏腹水癌细胞周期移行的影响,[J]河南医学院学报,1985,20(2):91-93.
[15]李学汤,林晨,李茵,等.七种人癌细胞系对冬凌草甲素的敏感性比较,[J]药学学报,1985,20(4):243-243.
[16]李学汤,林晨,李茵.冬凌草甲素体外杀细胞作用的特点,[J]中国药理学报,1986,7(4):361-361.
[17]左海军,李丹,吴斌,等.冬凌草的化学成分及其抗肿瘤活性,[J].沈阳药科大学学报,2005,7(22)258-262
[18]王绵英,林晨,张覃沐,等.冬凌草甲素对小白鼠血病L1210细胞动力学的影响,[J]中国药理学报,1985,6(3):195-195.
[19]冯长伟,潘祥林,邹俊晖,等.冬凌草甲素对人红白血病细胞系K562细胞生长的抑制作用,[J]山东中医药大学学报,2000,24(3):225-226.
[20]冯长伟,潘祥林,邹俊晖,等.冬凌草甲素对人白血病HL60细胞抑制作用的研究,[J]浙江中医中医学院学报,2000,24(3):47-49.
[21]申家英,杨波.冬凌草甲素对HL-60细胞的生长抑制作用及其对细胞端粒酶活性的调节,[J].白血病·淋巴瘤,2003,12(4):224-226.
[22]刘加军,陆惠玲,黄仁魏,等,冬凌草甲素对白血病HL60细胞的生长抑制作用,[J]中药新药与临床药理,2004,15(6)384-387.
[23]李瑞芳,王庆端.冬凌草甲素对K562细胞端粒酶活性调控及细胞周期的影响,[J].药学学报,2004,39(11):865-865.
[24]刘明月,范魁生,樊青霞,等.冬凌草甲素诱导结肠癌细胞凋亡的实验研究,[J].河南肿瘤学杂志,2004,6(17):167-168
[25]刘加军,陆惠玲,黄仁魏,等.冬凌草甲素对白血病NB4细胞的生长抑制作用,[J].中药新药与临床药理,2004,11(15):384-387
[26]Ohyashiki JH,Sashida G,Tauchi.T.Telomeres and telomerase in hematologic neoplasia,[J],Oncogene,2002,21(4):680-687
[27]Ji ZN,Ye WC,Rui J,etal.Patensin-induced apoptosis is accompanied By decreased bcl-2 expression and telomerase activity in HL-60 cells.[J]Asian Nat Prod Res,2004,6(2);1 07-114
[28]Nakajima A,Tauchi T,Sashida G,Telomerase inhibition enhances apoptosis in human acute leukemia cells;possibility of antitelomerase therapy,[J],Leukemia.2003,17(3);560-567.
[29]冯长伟,潘祥林,邹俊辉,等.冬凌草甲素对人白血病K562细胞抑制作用的研究,[J].浙江中医学院学报,2000,24(3):47-48.
[30]郭娟娟,潘祥林,冯长伟,等.冬凌草甲素逆转多药耐药细胞系K562/A02耐药性的研究,[J].上海医学,2002,25(1):43-45.
[31]刘加军,潘祥林,伍新尧,等。冬凌草甲素诱导白血病K562细胞凋亡的机制,肿瘤研究与临床;2003,8(15):222-225.
[32]吴孔明,张覃林,王庆端,等.冬凌草甲素对肿瘤细胞钠泵活性的影响,[J]肿瘤防治研究,1994,21(4):208-209.
[33]王绵英,林晨,张覃林.用放射自显影术研究冬凌草甲素对L 1210细胞DNA、RNA和蛋白质合成的影响,[J]中国药理学报,1987,8(2):164
[34]王绵英,马寿钢,张覃林.用显微光度术和放射自显影相结合的方法研究冬凌草甲素对小鼠白血病L1210和小鼠S180细胞动力学的影响,[J]河南医科大学学报,1986,21(1):24-25.
[35]Takay U,Yang Y,Kentaro B,etal.Oridonin,aditerpenoid Purified from Rabdosiam beseens,inhibits the Proliferation of cells from lylnoid malignaneies in association with blockade of the NF-kappaB siplyalpathwath,[J].Mol CaneerTher,2005,4(4):578-586.
[36]Leung CH,Grill SP,Lam W,et al.Novel mechanism of inhibition of nuelear factor-kappa B DNA-binding activity by diterpenoids isolated from Isodon rubeseens,[J].Mol Pharmaeol,2005,68(2):286-297.
[37]李瑛,张覃林.冬凌草甲素对体外无细胞DNA的影响[J].中国药理学报,1988,9(5):465.
[38]李瑛,张覃林.冬凌草甲素对小鼠肿瘤细胞核苷酸代谢的影响,[J].中国药理学报,1987,8(3):271-272.
[39]马寿钢,王绵英,王琪,等.冬凌草甲素和博菜霉素A5联合应用对肿瘤和骨 髓细胞DNA合成的影响,[J].中国药理学报,1987,8(1):83-83.
[40]申家英,杨波.冬凌草甲素对HL-60细胞的生长抑制作用及其对细胞端粒酶活性的调节,[J].白血病·淋巴瘤,2003,12(4):224-226.
[41]刘加军,伍新尧,潘祥林,等.冬凌草甲素对NB4细胞的诱导凋亡机制,[J].中成药,2003,25(11):900-902.
[42]刘加军,潘祥林,伍新尧,等.冬凌草甲素诱导白血病K562细胞凋亡的机制,[J].肿瘤研究与临床,2003,15(4):222-225.
[43]刘加军,潘祥林,伍新尧,等.冬凌草甲素对Raji细胞增殖抑制作用及机制,[J].中草药,2004,35(7):774-777.
[44]刘明月,范魁生,樊青霞,等.冬凌草甲素诱导结肠癌细胞凋亡的实验研究,[J].河南肿瘤学杂志,2004,17(3):167-168.
[45]张春玲,吴立军,左海军,等.冬凌草甲素通过线粒体途径诱导人黑色素瘤A375-S2细胞凋亡,[J].中草药,2004,35(4):423-426.
[46]张守伟,刘加军.复方冬凌草甲素对肺癌SPCA-1细胞的端粒酶活性的影响,[J].临床肺科杂志,2003,8(3):204-206.
[47]刘加军,伍新尧,潘祥林,等.γ-干扰素联合冬凌草甲素对白血病U937细胞的增生抑制作用,[J].白血病·淋巴瘤,2003,12(6):342-345.
[48]林碧莲,杨得坡,胡海燕.冬凌草甲素抗癌分子药理与临床应用策略,[J].广东医学,2000,10(4):5-8.
[49]杨胜利,韩绍印,张巧,等.冬凌草甲素抗突变性研究,[J].癌变·畸变·突变,2001,13(1):8-10.
[50]Ikezoe T,Chen S S,Tong XJ,et al.Oridonin induces growth the inhibition andapoptosis of avariety of human cancer cells,[J].IntJOncol,2003,23(4):1187-1193
[51]杨胜利.冬凌草甲素对人鼠肺及肝原代细胞非程序DNA合成的影响,[J].河南医科大学学报,2001,36(4):415-416.
[52]郭娟娟,潘祥林.冬凌草甲素诱导多耐药细胞系K562/ADR凋亡、逆转耐药性的研究,[J].安徽中医学院学报,2000,19(3):34-36.
[53]Gabellini C,Antonelli A,Petrinelli P,et al.Telomerase activity,apoptosis and cell cycle progression inataxia telangiectasia lymphocytes expressing TCL. [J].Br J Cancer, 2003,89(6):1091-1095.
[54] Fujita E, Nagao Y, Kaneko K, et al. The antitumor and antibacterial activity of the Isodon diterpenoids , [J]. Chem Pharm Bull, 1976, 24(9) :2118-2127.
[55] Fujita E, Nagao Y, Kohno T, et al. Antitumor activity of acylated Oridonin, [J]. Chem Pharm Bull, 1981, 29(11): 3208-3213.
[56] Node M, Sai M, Fuji K, et al. Antitumor activity of diterpenoids, trichorabdals A, B, and C, and the related compounds: synergism of two activities, [J]. Chem Pharm Bull, 1983, 31(4):1433-1436.
[2] Ham SJ, Schraffordt Koopsh, Vander Graaf WT, et al. Historical, current and future aspects of osteosarcoma treatment. Eur J Surg Oncol, 1998, 24(6):584-600
[3] Picci P, Ferrari S, Bacci G, et al. Treatment recommendation for osteosarcoma and adult soft tissue sarcoma. Drugs, 1994, 47: 82-92.
[4] Bramwell VH. The role of chemotherapy in the management of non-metastatic operable extremity osteosarcoma. Semin Oncol, 1997, 24(5): 561-571.
[5] Bacci G, Lari S. Current treatment of high grade osteosarcoma of the extremity. J Chemother, 2001,13: 235-243.
[6] Wafa H, Grimer RJ. Surgical options and outcomes in bone sarcoma. Expert Rev Anticancer Ther, 2006, 6: 239-248.
[7] Tsunemi T, Nagoya S, Kaya M, et al. Postoperative progression of pulmonary metastasis in osteosarcoma. Clin Orthop Relat Res, 2003, 407:159-166.
[8] Yance DR, Sarga SM. Targeting angiogenesis with integrative cancer therapies. Integr Cancer Ther, 2006, 5(1): 9-29.
[9] Gonzales GF, Valerio LG. Medicinal plants from Peru: a review of plants as potential agents against cancers. Anticancer Agents Med Chem, 2006, 6(5):429-444.
[10] de la Taille A, Hayek OR, Burchardt M, et al. Role of herbal compounds (PC-SPES) in hormone-refractory prostate cancer: Two case reports. J Altern Complement Med 2000, 6: 449-451.
[11] Li XT, Lin C, Li PY. Characteristics of the cytostatic effects of oridonin in vitro. Acta Pharmacol Sin, 1986, 7:361-363.
[12] Ikezoe T, Chen S, Heber D, et al. Baicalin is a major component of PC-SPES which inhibits the proliferation of human cancer cells via apoptosis and cell cycle arrest. Prostate, 2001, 49: 285-292.
[13] Hsieh TC, Wijeratne EK, Liang JY, et al. Differential control of growth, cell cycle progression, and expression of NF-kappaB in human breast cancer cells MCF-7, MCF-10A, and MDA-MB-231 by ponicidin and oridonin, diterpenoids from the chinese herb Rabdosia rubescens. Biochem Biophys Res Commun,2005, 337(1): 224-231.
[14] Zhang JF, Liu JJ, Liu PQ, et al. Oridonin inhibits cell growth by induction of apoptosis on human hepatocellular carcinoma BEL-7402 cells. Hepatol Res,2006, 35:104-110.
[15] Leung CH, Grill SP, Lam W, et al. Novel mechanism of inhibition of nuclear factor-kappa B DNA-binding activity by diterpenoids isolated from Isodon rubescens. Mol Pharmacol, 2005, 68: 286-297.
[16] Ikezoe T, Yang Y, Bandobashi K, et al. Oridonin, a diterpenoid purified from Rabdosia rubescens, inhibits the proliferation of cells from lymphoid malignancies in association with blockade of the NF-kappa B signal pathways.Mol Cancer Ther, 2005, 4(4): 578-586.
[17] Ikezoe T, Chen SS, Tong XJ, et al. Oridonin induces growth the inhibition and apoptosis of a variety of human cancer cells. Int J Oncol, 2003, 23(4):1187-1193.
[18] Gabellini C, Antonelli A, Petrinelli P, et al. Telomerase activity, apoptosis and cell cycle progression in ataxia telangiectasia lymphocytes expressing TCL 1. Br J Cancer, 2003, 89(6): 1091-1095.
[19] Liu YQ, You S, Tashiro S, et al. Activation of phosphoinositide 3-kinase, protein kinase C, and extracellular signal-regulated kinase is required for oridonin-enha-nced phagocytosis of apoptotic bodies in human macrophage-like U937 cells. J Pharmacol Sci, 2005, 98: 361-371.
[20] Khar A, Ali AM, Pardhasaradhi BV. Induction of stress response renders human tumor cell lines resistant to curcumin-mediated apoptosis: role of reactive oxygen intermediates. Cell Stress Chaperones, 2001, 6(4): 368-376.
[21] Gao ZG, Ye QX, Zhang TM. Synergistic effect of oridonin and cisplatin on cytotoxicity and DNA cross-link against mouse sarcoma S180 cells in culture. Zhong Guo Yao Li Xue Bao,1993,14(6):561-564.
[22]Huang J,Wu L,Tashiro S,et al.Bcl-2 up-regulation and P-p53 down-regulation account for the low sensitivity of murine L929 fibrosarcoma cells to oridonin-induced apoptosis.Biol Pharm Bull,2005,28(11):2068-2074.
[23]司徒镇强,吴军正.细胞培养.西安:世界图书出版公司,2004,1-378.
[24]白丽,邬利娅,伊明,等.赤土茯苓对正常小鼠免疫功能的影响.新疆医科大学学报,2003,26(6):573-574.
[25]冯长伟,潘祥林,邹俊晖,等.冬凌草甲素对人红白血病细胞系K562生长的抑制作用.山东中医药大学学报,2000,24(3):225-226.
[26]Zhang CL,Wu LJ,Tashiro S,et al.Oridonin induced A375-S2 cell apoptosis via bax-regulated caspase pathway activation,dependent on the cytochrome c/caspase-9 apoptosome.J Asian Nat Prod Res,2004,6(2):127-138.
[27]Huang J,Wu L,Tashiro S,et al.Fibroblast growth factor-2 suppresses oridonin-induced L929 apoptosis through extracellular signal-regulated kinase-dependent and phosphatidylinositol 3-kinase-independent pathway.J Pharmacol Sci,2006,102(3):305-313.
[28]Li D,Wu LJ,Tashiro S,et al.Oridonin-induced A431 cell apoptosis partially through blockage of the Ras/Raf/Erk signal pathway.J Pharmacol Sci,2007,103(1):56-66.
[29]Liu YQ,You S,Tashiro S,et al.Oridonin induced U937 cell apoptosis through ERK pathway.Zhongguo Zhong Yao Za Zhi,2005,30(23):1856-1859.
[30]Kerr JFR,Wyllie AH,Currie AR.Apoptosis:a basic biological phenomenon with wide-ranging implications in tissue kinetics.Br J Cancer,1972,26:239-257.
[31]Kiechle FL,Zhang X.Apoptosis:biochemical aspects and clinical implications.Clin Chim Act,2002,326(1-2):27-45.
[32]Raynal P,Pollard HB.Annexins:the problem of assessing the biological role for a gene family of multifunctional calcium-and phospholipid-binding proteins.Biochim Biophys Acta.1994,1197(1):63-93.
[33]Vermes I,Haanen C,Steffens-Nakken H,et al.A novel assay for apoptosis:flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods, 1995,184(1): 39-51.
[34] Martin SJ, Reutelingsperger CP, McGahon AJ, et al. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J Exp Med, 1995,182(5): 1545-156.
[35] Koopman G, Reutelingsperger CP, Kuijten GA. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood, 1994, 84(5): 1415-1420.
[36] Homburg CH, de Haas M, von dem Borne AE, et al. Human neutrophils lose their surface Fc gamma RIII and acquire Annexin V binding sites during apoptosis in vitro. Blood, 1995, 85(2): 532-540.
[37] Mullauer L, Gruber P, Sebinger D, et al. Mutations in apoptosis genes: a pathogenetic factor for human disease. Mutat Res, 2001,488: 211-231.
[38] Kiechle FL, Zhang X. Apoptosis: a brief review. J Clin Ligand Assay, 1998, 21:58-61.
[39] Zimmerman KC, Bonzon C, Green DR. The machinery of programmed cell death. Pharmacol Ther, 2002, 92: 57-70.
[40] Reed JC. Mechanisms of apoptosis. Am J Pathol, 2000,157:1415-1430.
[41] Elledge SJ. Cell cycle checkpoints: preventing an identify crisis. Science, 1996, 274:1664-1671.
[42] 来茂德.医学分子生物学.北京:人民卫生出版社, 1999, 40-54.
[43] Saldanha SN, Andrews LG, Tollefsbol TO. Assessment of telomere length and factors that contribute to its stability. Eur J Biochem, 2003, 270(3): 389-403.
[44] Bianchi A, Smith S, Chong L, et al. TRF1 is a dimer and bends telomere DNA. EMBOJ, 1997,16(7): 1785-1794.
[45] Ren KK, Wang HZ, Xie LP, et al. The effects of Oridonin on cell growth, cell cycle, cell migration and differentiation in melanoma cells. J Ethnopharmacol,2006,16(2): 176-180.
[46] Kroemer G. The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat Med, 1997, 3: 614-619.
[47]Green DR,Reed JC.Mitochondria and apoptosis.Science,1998,281:1309-1311.
[48]Grooss A,McDonnell JM,Korsmeyer SJ.Bcl-2 family members and the mitochondria in apoptosis.Genes Deu,1999,13:1899-1911.
[49]Joza N.Essential role of the mitochondria apoptosis-inducing factor in programmed cell death.Nature,2001,410(6828):549-554.
[50]Shi h.A structural view of mitochondria-mediated apoptosis.Nat Biol,2001,8(5):394-401.
[51]申家英,杨波.冬凌草甲素对HL-60细胞的生长抑制作用及其对细胞端粒酶活性的调节.白血病·淋巴瘤,2003,12(4):224-226.
[52]Adida C,Crotty PL,Mcgrath J,et al.Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse proliferation.Am J Pathol,1998,152(1):43.
[53]Konno R,Yamakawa H,Utsunomiya H,et al.Expression of survivin and bcl-2 in the normal human endometrium.Mol Hum Reprod,2000,6(6):529.
[54]Shin S,Sung BJ,ChoYS,et al.An anti-apoptotic protein human survivor is a direct inhibitor of caspase-3 and caspase-7.Biochemistry,2001,40(4):1117-1123.
[55]Li F,Ambrosini G,Chu EY,et al.Control of apoptosis and mitotic spindle checkpoint by survivin.Nature(Lond),1998,396(6711):580-584.
[56]Suzuki A,Ito T,Kowano H,et al.Survivin initiates procaspase-3/p21 complex formation as a result of interaction with Cdk4 to resisit Fas-mediated death.Oncogene,2000,19:1346-1353.
[57]Sato N,Mizumoto K,Nagai E,et al.Telomerase as a new target for pancreatic cancer treatment.J Hepatobiliary Pancreat Surg,2002,9(3):322-327.
[58]Mese H,Ueyama Y,Suzuki A,et al.Inhibition of telomerase activity as a measure of tumor cell killing by cisplatin in squamous cell carcinoma cell line.Chemotherapy,2001,47(2):136-142.
[59]Jiang YA,Luo HS,Zhang YY,et al.Telomerase activity and cell apoptosis in colon cancer cell by human telomerase reverse transcriptase gene antisense oligodeoxynucleotide.World J Gastroenterol,2003,9(9):1981-1984.
[60]Gabellini C,Antonelli A,Petrinelli P,et al.Telomerase activity,apoptosis and cell cycle progression in ataxia telangiectasia lymphocytes expressing TCL1.Br J Cancer,2003,89(6):1091-1095.
[61]Zhu XL,Kumar R,Mandal M,et al.Cell cycle-dependent modulation of telomerase activity in tumor cells.Proc Natl Acad Sci USA,1996,93(7):6091-6095.
[62]Scott LA,Vass JK,Parkinson EK,et al.Invasion of normal human fibroblasts induced by v-Fos is independent of proliferation,immortalization,and the tumor suppressors p16INK4a and p53.Mol Cell Biol,2004,24(4):1540-1559.
[63]Kiyono T,Foster S,Koop JI,et al.Both Rb/P16~(INK4a)inactivity are required to immortalize human epithelial cells.Nature,1998,396(6706):84-88.
[64]Zhang LP,Jiang JK,Tam JW,et al.Effects of Matrine on proliferation and differentiation in K-562 cells.Leuk Res,2001,25(9):793-800.
[65]周峻,金岩,何勇,等.端粒酶抑制剂对舌癌细胞株端粒酶活性和细胞周期的作用.中国癌症杂志,2002,12(2):110-112.
[66]Noble JR,Zhong ZH,Neumann AA,et al.Alterations in the p16(INK4a)and p53 tumor suppressor genes of bTERT-immortalized buman fibroblasts.Oncogene,2004,23(17):3116-3121.
[67]李登举,张瑶珍,曹文静,等.细胞外调节蛋白激酶与端粒酶对肝癌和白血病细胞凋亡的调控作用研究.中国实验血液学杂志,2002,10(4):294-298.
[68]Nakatani K,Toshimi N,Mori H,et al.The significant role of telomerase activity in human brain tumors.Cancer,1997,80:471-472.
[69]Cong YS,Wright WE,Shay JW.Human telomerase and its regulation.Microbiol Mol Biol Rev,2002,66(3):407-425.
[70]Horikawa I,Cable PL,Afshari C,et al.Cloning and characterization of the promoter region of human telomerase reverse transcriptase gene.Cancer Res,1999,59(4):826-830.
[71]李瑞芳,王庆端.冬凌草甲素对K562细胞端粒酶活性调控及细胞周期的影响.药学学报,2004,39(11):865-868.
[72]Staddon AP,Lackman R,Robinson K,et al.Osteogenic sarcoma presenting with lung metastasis.Oncologist,2002,7(2):144-153.
[73]Thompson RC Jr,Cheng EY,Clohisy DR,et al.Results of treatment for metastatic osteosarcoma with neoadjuvant chemotherapy and surgery.Clin Orthop,2002,397:240-247.
[74]Kantor JO,Mccormick B,Steeg PS,et al.Inhibition of cell motility after nm23transfection of human and marine tumor cells.Cancer Res,1993,53(4):1971-1973.
[75]Miyasaka M.Cancer metastasis and adhesion molecules.Clin Orthop,1995,312:10-18.
[76]Opedenakker Q,Van Damme J.Chemotactic factors,passive invasion and metastasis of cancer cells.Immumol Today,1992,13(2):463-464.
[77]Balkwill F.Chemokine biology in cancer.Semin Immuno,2003,15(1):49-55.
[78]Itoh Y,Nagase H.Matrix metalloproteinases in cancer.Essays Biochem,2002,38:21-36.
[79]Cavallaro U,Christofori G.Cell adhesion in tumor invasion and metastasis:loss of the glue is not enough.Biochim Biophys Acta,2001,1552(1):39-45.
[80]Webb CP,Vande Woude GF.Genes that regulate metastasis and angiogenesis.J Neuro oncology,2000,50:71-87.
[81]韩锐,孙燕.新世纪癌的化学预防与药物治疗.第一版,北京:人民军医出版社,2005,307-319.
[82]Anitha J,George T.The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis.Patho Oncol Res,2004,7(1):14-23.
[83]Stanley Z,Cao J,Chen WT.Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment.Oncogene,2000,19(56):6642-6650.
[84]Kakeji Y,MaeharaY,Sumiyoshi Y,et al.Angiogenesis as a target for gastric cancer.Surgery,2002,131(1 Suppl):S48-54.
[85]Tosetti F,Ferrari N,De Flora S,et al.Angioprevention:angiogenesis is a common and key target for cancer chemopreventive agents.FASEB J,2002,16(1):2-14.
[86]Gerwins P,Skoldenberg E,Claesson Welsh L.Function of fibroblast growth factors and vascular endothelial growth factors and their receptors in angiogenesis. Crit Rev Oncol Hematol, 2000, 34(3): 185-194.
[87] Bruns CJ, Liu W, Davis DW, et al. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases. Cancer, 2000, 89(3): 488-499.
[88] Noda M, Hattori T, Kimura T, et al. Expression of fibroblast growth factor 2 mRNA in early and advanced gastric cancer. Acta Oncol, 1997, 36(7): 695-701.
[89] Meade-Tollin LC, Wijeratne EM, Cooper D, et al. Ponicidin and oridonin are responsible for the antiangiogenic activity of Rabdosia rubescens, a constituent of the herbal supplement PCSPES. J Nat Prod, 2004, 67(1): 2-4.
[90] Ren KK, Wang HZ, Xie LP, et al. The effects of oridonin on cell growth, cell cycle, cell migration and differentiation in melanoma cells. J Ethnopharmacol, 2006,103(2): 176-180.
[1] Rosen G, Tan C , Sanmaneechai A ,et al.The rationale for Multiple drug chemotherapy in the treatment of osteogenic sarcoma.[J]. Cancer, 1975,35(3S):936-945.
[2] Bramwell VH. The role of chemotherapy in the management of non- metastatic operable extremity osteosarcoma. [J] .Semin Oncol, 1997 , 24 (5): 561-571.
[3] Bacci G, Forni C, Ferrair S,et al.Neoadjuvant chemotherapy for osteo-sarcoma of extremity: Intensification of preoperative treatment does not increase the rate of good histologic response to the primary tumor or improve the final outcome.[J] .Pediatr Hematol Oncol, 2003, 25: 845-853.
[4] Goorin AM, SchwartzentruberDJ,DevidasM, et al. Presurgical chemtherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric oncolong groupstudy POG-8651. [J]. Clin Oncol, 2003,21:1574-1580.
[5] Eselgrim M, Grunert H, Kuhne T,et al. Dose intensity of chemotherapy for osteosarcoma and outcome in the cooperative osteosarcoma study group(COSS) trials. [J].Pediatr Blood Cancer. 2006, 47: 42-50.
[6] Wilkins RM , Cullen JW, Odom L, et al.Superior survival intreatment of primary nonmetastatic pediatric osteosarcoma of the extremity .[J].Ann Surg Oncol,2003 ,10 (5): 498-507.
[7] Abe S , Tateishi A , Ogawa K,et al . Long-term local intensive preoperative chemotherapy and joint-preserving conservative surgery for osteosarcoma around the knee. [J] .Ort hopedics , 2001,24 (7): 671-676.
[8] Fuchs N , Bielack SS , Epler D ,et al. Long-term results of the cooperative German-Aust rian-Swiss osteosarcoma study group, sprotocol COSS-86 of intensive multidrug chemotherapy and surgery for os teosarcoma of the limbs.[J].Ann Oncol, 1998 , 9 (8) :893-899.
[9]Scotland K, Baldni N, Serra M, et al. Adriamycin binding Assay:Avaluable chemosensitivity test in human osteosarcoma. [J]. Cancer Res Clin Oncol, 1992,119: 121-126.
[10] Baldini N, Scotlandi K, Serra M, et al.P-glycoprotein expression in osteosarcoma: A basis for risk-adapted adjuvant chemotherapy. [J] .OrthopRes, 1999, 17:629-632.
[11]SerraM,Scotlandi K,Reverter Branchat G,et al.Value of P-glycoprotein and linicopathologic factors as the basis for new treatment strategies in high-grand osteosarcoma of the extremities.[J].Clin Oncol,2003,21:536-542.
[12]Gasparini G.Metronomic scheduling:The future of chemotherapy.[J].Lan-cet Oncol,2001,2:640-733.
[13]Asada N,Tsuchiya H,Tomita K.Denovo deletions of p53 gene and wild-type p53 correlate with acquired cisplatin-resistance in human osteosarcoma OST cell line.[J].Anticancer Res,1999,19:5131-5137.
[14]于秀淳,刘晓平,周银,等.P糖蛋白在骨肉瘤组织中的表达与PCNA、p53、nm23蛋白表达的相关性.[J].中国矫形外科杂志,2000,7(3):224-226.
[15]严庆水,张惠平,苏增贵,等.珊瑚羟基磷灰石人工骨的研制和修复骨干缺损的实验研究.[J].中华骨科杂志,1996,11(4):726-728.
[16]范顺武,严世贵,杨迪生,等.保肢术结合辅助化疗治疗肢体B期骨肉瘤.[J].中华骨科杂志,2000,7(3):393-396.
[17]Luksch R,Perotti D,Cefalo G,et al.Immunomodulation in treatment program including pre-and post-operative interleukin-2 and chemotherapy for childhood osteosarcoma.[J].Tumor,2003,89(3):263-268.
[18]Liebau C,Roesel C,Schmidt S,et al.Immuno therapy by gene transfer with plasmids encoding IL-12/IL-18 is superior to IL-23/IL-18 gene transfer in a rat osteosarcoma mode.[J].Anticancer Res,2004,24(5A):2861-2867.
[19]Todesco A,Carli M,Iacona I,et al.All-trans retinoic acid and interferon-alpha in the treatment of a patient with resistant metastatic osteosarcoma,[J].Cancer,2000,89(12):2661-2666.
[20]Yee C.Thompson JA.Byrd D,et al.Adoptive T cell therapy using antigen specific CD8+ T cells.[J].Proc Natl Acad Sci USA,2002,99(25);16168-16173.
[21]Overwijk WW,Theoret MR,Findel stein SE,et al.Tumor Regression and Autoimmunity after Reversal of a Functionally Tolerant State of Self-reactive CD8+ T Cells.[J].ExpMed;2003;198(4);569-580.
[22]孙瑛勋,程绍辉,于鸣.等.CD3AK细胞过继免疫治疗的实验研究[J]细胞与分子免疫学杂志.2005;21(2);218-221
[23]Jiang J,Xu N,Wu C,et al.Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells.Anticancer Res,2006,26(3B):2237-2242.
[24]WongkajornsilpA.Sangsuriyong S.Hongeng S et al.Effective osteosarcoma cytolysis using cytokine-induced killer cells pre-inoculated with tumor RNA-pulsed dendritic cells.[J].OrthopRes,2005,23:1460-1466.
[25]Huang J,Kerstann KW,Ahmadzadeh M,et al,Modulation by IL-2 of CD70 and CD27 Expression on CD8~+ T Cells:Importance for the Therapeutic Effectiveness of Cell Transfer Immunotherapy.[J].Immunol,2006;176(12);7726-7735
[26]Nagaraj S Ziske C Schmidt-wolf IG,Human cytokine-induced killer cells have enhanced in vitro cytolytic activity via non-viral interleukin-2 gene transfer.[J].Genet Vaccines Ther,2004;2(1);12-14
[27]Ho WP.Yee C.Greeenberg PD.Adoptive therapy with CD8~+ T cells:it may get by with a little help from its friends.[J].Clin invest,2002;110(10);1415-1417.
[28]Ragland BD,BellWC,Lopez RR,et al.Cytogenetics and molecular biology of osteosarcoma.[J].Lab Invest,2002,82(4):365-373
[29]王桂龙,向阳,胡军.等.反义c-myc寡核苷酸对骨肉瘤MG-63细胞增殖和凋亡的影响.[J].中国骨肿瘤骨病,2007;2(6);14-17
[30]Cain K,Bratton SB,Langlais C,et al.Apaf-1 oligomerizes into biologically active approximately 700 kD and inactive ap2 proximately 114 MD apoptosome complexes.[J]Biol Chem,2000,275:6067-6070.
[31]蔡文涛,陈安民,郭风劲,等.HIF-1a反义寡核苷酸对骨肉瘤MG-63细胞HIF-1a、P53、Bcl-2表达及凋亡的影响.[J].中国癌症杂志,2006;11(16);948-852.
[32]Ravi R,Mookerjee B,Bhujwalla ZM,et al.Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1 alpha.[J].GenesDev,2000,14(1):34-44.
[33]段国庆,李书忠.凋亡抑制蛋白Survivin在骨肉瘤中的表达及其与PTEN cyclinD1蛋白表达的关系,[J].中国矫形外科杂志;2007;3(15);217-225.
[34]聂涛,戴闽,宗世璋.Survivin在骨肉瘤中的表达及其与血管内皮生长因子的相关性研究.[J].中国矫形外科杂志,2005,13(9):683-685.
[35]Trieb K,Lehner R,Stulnig T,et al.Survivin expression in human osteocarcoma is a marker for survival[J].Eur J Surg Oncol,2003,29(4):379-382.
[36]Conway EM,Pollefeyt S,Comelissen J,et al.Three differentially expressed Survivin cDNA variants encode proteins with distinct antiapoptosis function,[J].Blood,2000,95:1435-1442.
[37]Hollstein M,Sidransky D,Vogelstein B,et al.P53 mutation in human cancers.[J].Science,1991,253;49-53.
[38]李永昊,肖玉周,俞岚,等.P53、p16基因在骨肉瘤中表达及临床相关性研究.[J].中国骨肿瘤骨病,2007;3(6);162-167.
[39]AI-Mohanna MA,Manogaran PS,AI-Mukhalafi Z,et al.The tumor suppressor p16 INK4a)gene is a regulator of apoptosis induced by ultraviolet light and cisplatin[J].Oncogene,2004,23(1);201-212.
[40]Tsang WP,Chau SP,Fung KP,etal.Modulation of multidrug resistanceassociated protein 1(MRP1)by p53 mutant in Saos-2 cells.[J].Cancer Chemother Pharmacol,2003,51(2):161-166.
[41]Tsunemi T,Nagoya S,Kaya M,et al.Postopreative progression of pulmonary metastasis in osteosarcoma.[J].Clin OrthopRelat Res,2003,407:159-166.
[42]Semenza GL.Targeting HIF-1 for cancer therapy,[J].Nat Rev Cancer,2003,3:721-732.
[43]Mabjeesh NJ,Escuin D,LaVallee TM,et al.2ME2 inhibits tumor growth and angiogenesis by disrupting Microtubules and dysregulating HIF.[J].Cancer Cell,2003,3:363-375.
[44]吴强,杨述华,叶树楠,等.RNA干扰沉默缺氧诱导因子-1a治疗骨肉瘤的实验研究.[J].中华医学杂志,2005,85:409-413
[45]Takayama K,Ueno H,Nakanishi Y.Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ.[J].Cancer Res,2000,77:2169-2177.
[46]Charity RM,Foukas AF,Deshmukh NS,et al.Vascular endothelial growth factor expression in osteosarcoma.[J].Clin OrthopRelat Res,2006,448:193-198.
[47]Oda Y,Yamamoto H,Tamiya S,et al.CXCR4 and VEGF expression in the primary site and the metastatic site of human osteosarcoma:analysis with in a group of patients,all of whom developed lung metastasis.[J].Mod Pathol,2006,19:738-745.
[48]王燕,汪睿,乔慧,等.缺氧反应组件启动子表达反义血管内皮生长因子(VEGF)165cDNA靶向性抑制骨肉瘤细胞EGF表达.[J].中华病理杂志,2005,4:588-591.
[49]Falareau P,Champagne P,Poyet P,et al.Neovastat:a naturally occurring multifunctional antiangiogenic drug,in phase 3 clinical trials.[J].Semin Oncol, 2001,28:6-10.
[50]Kaya M,Wada T,Kawaguchi S,et al.Increased pre-therapeutic serum vascular endothelial growth factor in patients with early clinical relapse of osteosarcoma.[J].Br J Cancer,2002,86:864-869.
[51]OReilly MS,Boehm T,Shing Y,et al.Endostatin:an endogenous ingibitor of angiogenesis and tumour growth.[J].Cell,1997,88:277-285.
[52]Marshall E.Cancer therapy,set backs for endostatin.[J].Science,2002,295:2198-2199.
[53]Nyormoi O,Mills L,Rose RW,et al.An MMP-2/MMP-9 inhibitor,5a,enhances apoptosis induced by ligands of the YNF receptor superfamily in cancer cells.[J].Cell Death Differ,2003,10:558-569.
[54]吴朝阳,林建华.抑制血管生成治疗骨肉瘤的研究进展,[J].中国骨肿瘤骨病,2007,6;370-374.
[55]Masferrer JL,Leahy KM,Koki AT,et al.Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors.[J].Cancer Res,2000,60:1306-1311.
[56]肖涛,李康华,方建珍,等.三氧化二砷诱导骨肉瘤MG-3细胞凋亡的实验研究.[J].湖南省医科大学学报,2002,2;23-25.
[57]魏玲,王兴武,宋现让,等.三氧化二砷对人骨肉瘤细胞的体外效应.[J]中国药学杂志,2005,18;27-34
[58]王利民.苦参碱诱导骨肉瘤细胞凋亡的实验研究.[J].实用诊断与治疗杂志,2004,5;44-47
[59]陈永强,朱振安,戴克戎,等.蜂毒素对骨肉瘤细胞系细胞增殖的影响.[J]上海中医大学学院.2003,1;21-23.
[60]陈晓超,柯李晶,陈躬瑞,等。鹿茸粗提液对大鼠成骨肉瘤细胞增殖的调节作用.[J]中国中药杂志,2004,1;38-41.
[61]王进,沈靖南.粉防已碱逆转骨肉瘤细胞系多药耐药性的研究.[J].实用临床医学.2005,6;21-22
[62]王冠梁,王元,王琦中草药及其提取物治疗骨肉瘤的基础研究进展.[J].云南中医学院学报.2006,29(2);52-54.
[1]河南省医学科学研究所药理药化组,河南医学院化学教研组,云南省植物研究所植化室,等,一种新的抗肿瘤物质-冬凌草素[J].科学通报,1978,23(1):53-56
[2]Fujita T,Masudal I,Tka S,Fujita E.Antitumor aetivity of the Isodon diterpenoids:struetural requlrelnents for the activity,[J].ExPerientia,1976,32(2):203-206.
[3]刘晨江,赵志鸿.冬凌草的研究进展,[J].中国药学杂志,1998,33(10):577-581.
[4]刘净,梁敬钮,谢韬.冬凌草研究进展,[J].海峡药学,2004,16(2):1-7.
[5]冯长伟,潘祥林,邹俊晖,等.冬凌草甲素诱导HL60细胞凋亡的研究,[J]..山东医药,2000,40(6):7-8.
[6]王筠,刘清芸,华海婴,等.冬凌草甲素诱导HL60细胞凋亡[J]..中国药理学报,2001,17(4):402-405.
[7]栾凤君,杨纯正,马建国,等.一株人红白血病多药细胞系(K562/A02)的建立及其耐药特性的研究,[J]..中华肿瘤杂志,1993,15(2):101.
[8]郭娟娟,潘祥林,冯长伟,冬凌草甲素逆转多药耐药细胞系K562/A02耐药性的研究.上海医学,2002,25(1)34-35
[9]Li D,Wu LJ,Shiniehi T,etal.Oridonin-Indueed A431 Cell Apoptosis partially Through Blockage of the Ras、NFa、RK SignalPathway,[J].Phannaeol sci,2007,103(1):56-66.
[10]Huang J,Wu L,ShiniehiT,et al.A comparison of the 51,alpathwa between the TNF-a、INF-a and Oridonin-induced murine L929fibrosareoma cell death,[J].Aeta Med Okayama,2005,59(6):261-270.
[11]葛明,马用法,张中兴,等.冬凌草甲素和乙素对人肝癌BEL7402细胞株杀伤作用的研究,[J]药学通报,1981,16(5):6-7.
[12]刘加军,伍新尧,潘祥林,等.冬凌草甲素对ECA细胞的诱导凋亡机制,[J]中成药,2003,25(11):900-902
[13]王绵英,张覃沐.冬凌草甲素对几种肿瘤细胞M期作用机制的探讨,[J]癌症, 1984,8(2):84-85.
[14]寿马钢,张覃沐,薛绍白,等.用流式细胞光度术测定冬凌草甲素和博莱霉素A5合用对艾氏腹水癌细胞周期移行的影响,[J]河南医学院学报,1985,20(2):91-93.
[15]李学汤,林晨,李茵,等.七种人癌细胞系对冬凌草甲素的敏感性比较,[J]药学学报,1985,20(4):243-243.
[16]李学汤,林晨,李茵.冬凌草甲素体外杀细胞作用的特点,[J]中国药理学报,1986,7(4):361-361.
[17]左海军,李丹,吴斌,等.冬凌草的化学成分及其抗肿瘤活性,[J].沈阳药科大学学报,2005,7(22)258-262
[18]王绵英,林晨,张覃沐,等.冬凌草甲素对小白鼠血病L1210细胞动力学的影响,[J]中国药理学报,1985,6(3):195-195.
[19]冯长伟,潘祥林,邹俊晖,等.冬凌草甲素对人红白血病细胞系K562细胞生长的抑制作用,[J]山东中医药大学学报,2000,24(3):225-226.
[20]冯长伟,潘祥林,邹俊晖,等.冬凌草甲素对人白血病HL60细胞抑制作用的研究,[J]浙江中医中医学院学报,2000,24(3):47-49.
[21]申家英,杨波.冬凌草甲素对HL-60细胞的生长抑制作用及其对细胞端粒酶活性的调节,[J].白血病·淋巴瘤,2003,12(4):224-226.
[22]刘加军,陆惠玲,黄仁魏,等,冬凌草甲素对白血病HL60细胞的生长抑制作用,[J]中药新药与临床药理,2004,15(6)384-387.
[23]李瑞芳,王庆端.冬凌草甲素对K562细胞端粒酶活性调控及细胞周期的影响,[J].药学学报,2004,39(11):865-865.
[24]刘明月,范魁生,樊青霞,等.冬凌草甲素诱导结肠癌细胞凋亡的实验研究,[J].河南肿瘤学杂志,2004,6(17):167-168
[25]刘加军,陆惠玲,黄仁魏,等.冬凌草甲素对白血病NB4细胞的生长抑制作用,[J].中药新药与临床药理,2004,11(15):384-387
[26]Ohyashiki JH,Sashida G,Tauchi.T.Telomeres and telomerase in hematologic neoplasia,[J],Oncogene,2002,21(4):680-687
[27]Ji ZN,Ye WC,Rui J,etal.Patensin-induced apoptosis is accompanied By decreased bcl-2 expression and telomerase activity in HL-60 cells.[J]Asian Nat Prod Res,2004,6(2);1 07-114
[28]Nakajima A,Tauchi T,Sashida G,Telomerase inhibition enhances apoptosis in human acute leukemia cells;possibility of antitelomerase therapy,[J],Leukemia.2003,17(3);560-567.
[29]冯长伟,潘祥林,邹俊辉,等.冬凌草甲素对人白血病K562细胞抑制作用的研究,[J].浙江中医学院学报,2000,24(3):47-48.
[30]郭娟娟,潘祥林,冯长伟,等.冬凌草甲素逆转多药耐药细胞系K562/A02耐药性的研究,[J].上海医学,2002,25(1):43-45.
[31]刘加军,潘祥林,伍新尧,等。冬凌草甲素诱导白血病K562细胞凋亡的机制,肿瘤研究与临床;2003,8(15):222-225.
[32]吴孔明,张覃林,王庆端,等.冬凌草甲素对肿瘤细胞钠泵活性的影响,[J]肿瘤防治研究,1994,21(4):208-209.
[33]王绵英,林晨,张覃林.用放射自显影术研究冬凌草甲素对L 1210细胞DNA、RNA和蛋白质合成的影响,[J]中国药理学报,1987,8(2):164
[34]王绵英,马寿钢,张覃林.用显微光度术和放射自显影相结合的方法研究冬凌草甲素对小鼠白血病L1210和小鼠S180细胞动力学的影响,[J]河南医科大学学报,1986,21(1):24-25.
[35]Takay U,Yang Y,Kentaro B,etal.Oridonin,aditerpenoid Purified from Rabdosiam beseens,inhibits the Proliferation of cells from lylnoid malignaneies in association with blockade of the NF-kappaB siplyalpathwath,[J].Mol CaneerTher,2005,4(4):578-586.
[36]Leung CH,Grill SP,Lam W,et al.Novel mechanism of inhibition of nuelear factor-kappa B DNA-binding activity by diterpenoids isolated from Isodon rubeseens,[J].Mol Pharmaeol,2005,68(2):286-297.
[37]李瑛,张覃林.冬凌草甲素对体外无细胞DNA的影响[J].中国药理学报,1988,9(5):465.
[38]李瑛,张覃林.冬凌草甲素对小鼠肿瘤细胞核苷酸代谢的影响,[J].中国药理学报,1987,8(3):271-272.
[39]马寿钢,王绵英,王琪,等.冬凌草甲素和博菜霉素A5联合应用对肿瘤和骨 髓细胞DNA合成的影响,[J].中国药理学报,1987,8(1):83-83.
[40]申家英,杨波.冬凌草甲素对HL-60细胞的生长抑制作用及其对细胞端粒酶活性的调节,[J].白血病·淋巴瘤,2003,12(4):224-226.
[41]刘加军,伍新尧,潘祥林,等.冬凌草甲素对NB4细胞的诱导凋亡机制,[J].中成药,2003,25(11):900-902.
[42]刘加军,潘祥林,伍新尧,等.冬凌草甲素诱导白血病K562细胞凋亡的机制,[J].肿瘤研究与临床,2003,15(4):222-225.
[43]刘加军,潘祥林,伍新尧,等.冬凌草甲素对Raji细胞增殖抑制作用及机制,[J].中草药,2004,35(7):774-777.
[44]刘明月,范魁生,樊青霞,等.冬凌草甲素诱导结肠癌细胞凋亡的实验研究,[J].河南肿瘤学杂志,2004,17(3):167-168.
[45]张春玲,吴立军,左海军,等.冬凌草甲素通过线粒体途径诱导人黑色素瘤A375-S2细胞凋亡,[J].中草药,2004,35(4):423-426.
[46]张守伟,刘加军.复方冬凌草甲素对肺癌SPCA-1细胞的端粒酶活性的影响,[J].临床肺科杂志,2003,8(3):204-206.
[47]刘加军,伍新尧,潘祥林,等.γ-干扰素联合冬凌草甲素对白血病U937细胞的增生抑制作用,[J].白血病·淋巴瘤,2003,12(6):342-345.
[48]林碧莲,杨得坡,胡海燕.冬凌草甲素抗癌分子药理与临床应用策略,[J].广东医学,2000,10(4):5-8.
[49]杨胜利,韩绍印,张巧,等.冬凌草甲素抗突变性研究,[J].癌变·畸变·突变,2001,13(1):8-10.
[50]Ikezoe T,Chen S S,Tong XJ,et al.Oridonin induces growth the inhibition andapoptosis of avariety of human cancer cells,[J].IntJOncol,2003,23(4):1187-1193
[51]杨胜利.冬凌草甲素对人鼠肺及肝原代细胞非程序DNA合成的影响,[J].河南医科大学学报,2001,36(4):415-416.
[52]郭娟娟,潘祥林.冬凌草甲素诱导多耐药细胞系K562/ADR凋亡、逆转耐药性的研究,[J].安徽中医学院学报,2000,19(3):34-36.
[53]Gabellini C,Antonelli A,Petrinelli P,et al.Telomerase activity,apoptosis and cell cycle progression inataxia telangiectasia lymphocytes expressing TCL. [J].Br J Cancer, 2003,89(6):1091-1095.
[54] Fujita E, Nagao Y, Kaneko K, et al. The antitumor and antibacterial activity of the Isodon diterpenoids , [J]. Chem Pharm Bull, 1976, 24(9) :2118-2127.
[55] Fujita E, Nagao Y, Kohno T, et al. Antitumor activity of acylated Oridonin, [J]. Chem Pharm Bull, 1981, 29(11): 3208-3213.
[56] Node M, Sai M, Fuji K, et al. Antitumor activity of diterpenoids, trichorabdals A, B, and C, and the related compounds: synergism of two activities, [J]. Chem Pharm Bull, 1983, 31(4):1433-1436.